全文获取类型
收费全文 | 4451篇 |
免费 | 200篇 |
国内免费 | 17篇 |
专业分类
耳鼻咽喉 | 44篇 |
儿科学 | 83篇 |
妇产科学 | 98篇 |
基础医学 | 202篇 |
口腔科学 | 100篇 |
临床医学 | 450篇 |
内科学 | 692篇 |
皮肤病学 | 44篇 |
神经病学 | 141篇 |
特种医学 | 78篇 |
外科学 | 463篇 |
综合类 | 151篇 |
一般理论 | 15篇 |
预防医学 | 1260篇 |
眼科学 | 84篇 |
药学 | 381篇 |
1篇 | |
中国医学 | 59篇 |
肿瘤学 | 322篇 |
出版年
2023年 | 135篇 |
2022年 | 148篇 |
2021年 | 338篇 |
2020年 | 188篇 |
2019年 | 667篇 |
2018年 | 433篇 |
2017年 | 248篇 |
2016年 | 146篇 |
2015年 | 146篇 |
2014年 | 231篇 |
2013年 | 286篇 |
2012年 | 202篇 |
2011年 | 195篇 |
2010年 | 110篇 |
2009年 | 105篇 |
2008年 | 115篇 |
2007年 | 79篇 |
2006年 | 70篇 |
2005年 | 62篇 |
2004年 | 65篇 |
2003年 | 57篇 |
2002年 | 38篇 |
2001年 | 35篇 |
2000年 | 27篇 |
1999年 | 23篇 |
1998年 | 45篇 |
1997年 | 46篇 |
1996年 | 35篇 |
1995年 | 51篇 |
1994年 | 50篇 |
1993年 | 35篇 |
1992年 | 29篇 |
1991年 | 18篇 |
1990年 | 6篇 |
1989年 | 8篇 |
1988年 | 3篇 |
1986年 | 3篇 |
1985年 | 16篇 |
1984年 | 17篇 |
1983年 | 22篇 |
1982年 | 12篇 |
1981年 | 13篇 |
1980年 | 14篇 |
1979年 | 12篇 |
1978年 | 13篇 |
1977年 | 7篇 |
1976年 | 18篇 |
1975年 | 14篇 |
1974年 | 16篇 |
1973年 | 8篇 |
排序方式: 共有4668条查询结果,搜索用时 312 毫秒
41.
Isabel M. A. Brüggenwirth Maureen J. M. Werner René Adam Wojciech G. Polak Vincent Karam Michael A. Heneghan Arianeb Mehrabi Jürgen L. Klempnauer Andreas Paul Darius F. Mirza Johann Pratschke Mauro Salizzoni Daniel Cherqui Michael Allison Olivier Soubrane Steven J. Staffa David Zurakowski Robert J. Porte Vincent E. de Meijer all the other contributing centers the European Liver Intestine Transplant Association 《Transplant international》2021,34(10):1928-1937
High-risk combinations of recipient and graft characteristics are poorly defined for liver retransplantation (reLT) in the current era. We aimed to develop a risk model for survival after reLT using data from the European Liver Transplantation Registry, followed by internal and external validation. From 2006 to 2016, 85 067 liver transplants were recorded, including 5581 reLTs (6.6%). The final model included seven predictors of graft survival: recipient age, model for end-stage liver disease score, indication for reLT, recipient hospitalization, time between primary liver transplantation and reLT, donor age, and cold ischemia time. By assigning points to each variable in proportion to their hazard ratio, a simplified risk score was created ranging 0–10. Low-risk (0–3), medium-risk (4–5), and high-risk (6–10) groups were identified with significantly different 5-year survival rates ranging 56.9% (95% CI 52.8–60.7%), 46.3% (95% CI 41.1–51.4%), and 32.1% (95% CI 23.5–41.0%), respectively (P < 0.001). External validation showed that the expected survival rates were closely aligned with the observed mortality probabilities. The Retransplantation Risk Score identifies high-risk combinations of recipient- and graft-related factors prognostic for long-term graft survival after reLT. This tool may serve as a guidance for clinical decision-making on liver acceptance for reLT. 相似文献
42.
43.
44.
45.
46.
47.
48.
从药材及饮片(植物药)的包件取样、包件内取样及试验样品制备等方面对《中国药典》(Chinese Pharmacopoeia,ChP)、《欧洲药典》(European Pharmacopoeia,EP)、《英国药典》(British Pharmacopoeia,BP)及《美国药典》(United States Pharmacopoeia,USP)进行对比,结合新药用饮片检验的要求,就中药新药用饮片取样法存在的问题进行探讨,并提出以下建议:(1)相关部门组织专家起草中药新药用饮片取样的指导原则或技术要求。(2)暂时参照EP、BP的取样法对中药新药用饮片进行研究,并关注饮片取样对检验结果的影响。(3)根据试验样品的特点研究确定其处理方法。如饮片的不同药用部位或位置的质量差异大,可采用分层抽样的方法,减少取样误差。(4)加强药材的源头管理,减少药材质量差异。(5)在新药用饮片的生产过程中采用混合步骤提高同批饮片的同质性。(6)在ChP“中药材及饮片取样办法”中增加:待检批次饮片应具有较好的同质性;有些样品或试验需要采用更严格的取样方法,包括更多取样包件数或包件内取样量;此外,可对包件内抽取的位... 相似文献
49.
Joseph J. Alukal Talan Zhang Paul J. Thuluvath 《American journal of transplantation》2021,21(6):2211-2219
There is a paucity of data on the outcome of liver transplantation (LT) in Budd-Chiari Syndrome (BCS) patients who are listed as status 1. The objective of our study was to determine patient or graft survival following LT in status 1 BCS patients. We utilized United Network for Organ Sharing (UNOS) database to identify all adult patients (> 18 years of age) listed as status 1 with a primary diagnosis of BCS in the United States from 1998 to 2018, and analyzed their outcomes and compared it to non-status 1 BCS patients. Four hundred and forty-six patients with BCS underwent LT between 1998 and 2018, and of these 55 (12.3%) were listed as status 1. There was no difference in long-term post-liver transplant or “intention-to-treat” survival from the time of listing to death or the last day of follow-up between status 1 and non-status 1 groups. Graft and patient survival at 5 years for status 1 patients were 75% and 82%, respectively. Cox regression analysis showed that patients listed as status 1 (aHR: 0.45, p < .02) were associated with a better survival. BCS patients listed as status 1 have excellent survival following emergency LT. 相似文献
50.
Liza Johannesson Anji Wall Andreas Tzakis Cristiano Quintini Elliott G. Richards Kathleen O’Neill Paige M. Porrett Giuliano Testa 《American journal of transplantation》2021,21(5):1699-1704
The parallel emergence of uterus transplantation (UTx) and other transplantation innovations including face and hand transplantation led to the categorization of the uterus as a vascular composite allograft (VCA). With >60 transplants and >20 births worldwide, UTx is transitioning rapidly from a research endeavor to an effective treatment option for women with uterine factor infertility. While it originally made sense to group the innovations under one umbrella, it is time to revisit the designation of UTx as a VCA. We describe how UTx needs unique policy, procedural codes, insurance contracts, and educational initiatives. We contend that separating UTx from VCAs may become necessary in the future to avoid hindering the growth and regulation of this field. 相似文献